TRAW (Traws Pharma) Insider Ownership: 8.73 % (As of Sep. 03, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TRAW Traws Pharma Inc TRAW
41 GF Score
Price $0.58
GF Value $9.30
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Traws Pharma Insider Ownership?

Traws Pharma TRAW +1.75% 41 Insider Ownership is 8.73 % as of Sep. 03, 2026. GuruFocus rates TRAW with a GF Score™ of 41/100 and a GF Value™ of $9.30 (Possible Value Trap). The stock has 4 warning signs investors should review.

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Traws Pharma's insider ownership is 8.73%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Traws Pharma's Institutional Ownership is 40.33%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Traws Pharma's Float Percentage Of Total Shares Outstanding is 84.96%.

Traws Pharma Insider Ownership Historical Data

* Premium members only.

The historical data trend for Traws Pharma's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Traws Pharma Insider Ownership Chart

Traws Pharma Historical Data

The historical data trend for Traws Pharma can be seen below:

2025-08-31 2025-09-30 2025-10-31 2025-11-30 2026-01-31 2026-02-28 2026-05-31 2026-06-30 2026-07-31 2026-08-31
Insider Ownership 18.34 18.34 18.18 18.18 18.43 18.43 8.77 8.77 8.73 8.73
TRAW
41GF Score
Traws Pharma Inc TRAW
Insider Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Traws Pharma Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Frequently Asked Questions Learn more about Insider Ownership →
What does a Insider Ownership of 8.73 % mean?
Traws Pharma (TRAW) has a Insider Ownership of 8.73 % as of Sep. 03, 2026. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Traws Pharma and its competitors.
Is Traws Pharma's Insider Ownership too high?
Traws Pharma's current Insider Ownership is 8.73 %. Overall, Traws Pharma has a GF Score™ of 41/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Traws Pharma's Insider Ownership compare to OSRH and IMNN?
Traws Pharma's Insider Ownership of 8.73 % can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Insider Ownership for a Biotechnology company?
A good Insider Ownership depends on the Biotechnology industry context. However, Insider Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Insider Ownership mean?
A high Insider Ownership can signal that a stock is expensive relative to its fundamentals. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Traws Pharma and its competitors. Traws Pharma's current Insider Ownership is 8.73 %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Traws Pharma stock overvalued right now?
Based on GuruFocus' analysis, Traws Pharma (TRAW) is currently considered Possible Value Trap. The stock's GF Value™ is $9.30, compared to a current price of $0.58 — trading 93.8% below its estimated fair value. The current Insider Ownership is 8.73 %. Traws Pharma's overall GF Score™ is 41/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Insider Ownership calculated?
Insider Ownership is calculated from a company's financial statements. For Traws Pharma (TRAW), the current Insider Ownership is 8.73 % as of Sep. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Traws Pharma (TRAW) Overvalued in 2026?

Based on GuruFocus' analysis, Traws Pharma stock appears to be undervalued. The current stock price of $0.58 is trading 93.8% below its estimated GF Value™ of $9.30. GuruFocus considers Traws Pharma to be Possible Value Trap.

Key valuation signals for TRAW:

  • Insider Ownership: 8.73 %
  • GF Value™: $9.30 vs. price of $0.58 (93.8% below fair value)
  • GF Score™: 41/100 with 4 warning signs

No single metric tells the full story. See the TRAW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Traws Pharma Business Description

Address 12 Penns Trail, Newtown, PA, USA, 18940
Traws Pharma Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It is advancing novel investigational antiviral agents that have potent activity against difficult-to-treat or resistant virus strains that threaten human health. Its product candidates are Tivoxavir marboxil, Ratutrelvir, and Narazaciclib. The company has four clinical programs: (i) tivoxavir marboxil, (ii) ratutrelvir, (iii) narazaciclib (ON 123300), and (iv) rigosertib. It is focused on the development of tivoxavir marboxil and ratutrelvir. The company derives revenue from its collaboration and licensing agreements.
41GF Score

Get the complete analysis for TRAW

Insider Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.58
Price
$9.30
GF Value